GLP-1 and calcitonin concentration in humans: Lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 3, 2011, Pages 853-860

  Hegedüs, Laszlo ^a   Moses, Alan C ^b   Zdravkovic, Milan ^c   Le Thi, Tu ^c   Daniels, Gilbert H ^d  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b NOVO NORDISK INC   (United States)

^c NOVO NORDISK A S   (Denmark)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; LIRAGLUTIDE; METFORMIN; PLACEBO; TETRAHYDROLIPSTATIN;

ADULT; ARTICLE; CALCITONIN BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HORMONE RELEASE; HORMONE RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDULLARY CARCINOMA; NODULAR HYPERPLASIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; CALCITONIN; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OBESITY; RECEPTORS, GLUCAGON;

RODENTIA;

EID: 79952284556     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-2318     Document Type: Article

References (23)

1. Costante G, Durante C, Francis Z, Schlumberger M, Filetti S 2009 Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. Nat Clin Pract Endocrinol Metab 5:35-44
2. Leboulleux S, Baudin E, Travagli JP, Schlumberger M 2004 Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 61:299-310 (Pubitemid 39287058)
3. Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, Gotfredsen C, Egerod FL, Hegelund AC, Jacobsen H, Jacobsen SD, Moses AC, Mølck AM, Nielsen HS, Nowak J, Solberg H, Thi TD, Zdravkovic M 2010 Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151:1473-1486
4. Martín-Lacave I, Bernab R, Sampedro C, Conde E, Fernández-Santos JM, San Martín MV, Beato A, Galera-Davidson H 1999 Correlation between gender and spontaneous C-cell tumors in the thyroid gland of the Wistar rat. Cell Tissue Res 297:451-457 (Pubitemid 29410533)
5. Capen CC, Martin SL 1989 The effects of xenobiotics on the structure and function of thyroid follicular and C-cells. Toxicol Pathol 17:266-293 (Pubitemid 19218938)
6. Körner M, Stöckli M, Waser B, Reubi JC 2007 GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 48:736-743 (Pubitemid 47604973)
7. Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S 2009 Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in patients with type 2 diabetes (LEAD-1 SU). Diabet Med 26:268-278
8. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR 2009 Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes. Diabetes Care 32:84-90
9. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B 2009 Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373:473-481
10. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L 2009 Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 32:1224-1230
11. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simó R 2009 Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU). Diabetologia 52:2046-2055
12. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L 2009 Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374:39-47
13. Kaku K, Rasmussen MF, Clauson P, Seino Y 2010 Improved glycaemic control with minimal hypoglycaemia and no weight gain with the once-daily human GLP-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab 12:341-347
14. Seino Y, Rasmussen MF, Nishida T, Kaku K 2010 Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin 26:1013-1022
15. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME; NN8022-1807 Study Group 2009 Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374:1606-1616
16. Erdogan MF, Gursoy A, Kulaksizoglu M 2006 Long-term effects of elevated gastrin levels on calcitonin secretion. J Endocrinol Invest 29:771-775 (Pubitemid 44869420)
17. Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, Crocetti U, Attard M, Maranghi M, Torlontano M, Filetti S 2007 Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 92:450-455
18. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Søndergaard RE, Davies M; 1860-LIRA-DPP-4 Study Group 2010 Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 375:1447-1456
19. Food and Drug Administration 2005 Byetta (exenatide), pharmacology review 2005. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2005/ 021773-Byetta-pharmr.PDF
20. Okada H, Toyota N, Harimaya Y, Matsukawa K 1991 Immunohistochemical alterations of C cells in sheep treated with vitamin D. J Comp Pathol 105:263-270
21. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells Jr SA 2009 Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565-612
22. Guyétant S, Rousselet MC, Durigon M, Chappard D, Franc B, Guerin O, Saint-André JP 1997 Sex-related C cell hyperplasia in the normal human thyroid: a quantitative autopsy study. J Clin Endocrinol Metab 82:42-47
23. Guyétant S, Bléchet C, Saint-André JP 2006 C-cell hyperplasia. Ann Endocrinol (Paris) 67:190-197